• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 425 filed by FoxWayne Enterprises Acquisition Corp.

    1/19/23 4:16:32 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FOXW alert in real time by email
    425 1 form425.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): January 12, 2023

     

    FOXWAYNE ENTERPRISES ACQUISITION CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-39891   85-3093926
    (State or other jurisdiction   (Commission   (I.R.S. Employer
    of incorporation)   File Number)   Identification No.)

     

    1 Rockefeller Plaza, Suite 1039

    New York, New York 10020

    (Address of principal executive offices, including zip code)

     

    Registrant’s telephone number, including area code: (917) 284-8938

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Units, each consisting of one share of Class A Common Stock and one Redeemable Warrant to purchase one share of Class A common stock   FOXWU   The Nasdaq Stock Market LLC
    Class A Common Stock, par value $0.0001 per share   FOXW   The Nasdaq Stock Market LLC
    Redeemable Warrants, each exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share   FOXWW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.02. Termination of Material Definitive Agreement

     

    As previously disclosed, on September 16, 2022, FoxWayne Enterprises Acquisition Corp., a Delaware corporation (“FoxWayne”), entered into an Agreement and Plan of Merger (“Merger Agreement”), by and among FoxWayne, Gotham Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of FoxWayne (“Merger Sub”), Clover Inc., a corporation organized under the laws of Ontario (“Clover”), and the stockholders’ representative.

     

    On January 12, 2023, by mutual agreement, the parties entered into a letter agreement to terminate the Merger Agreement pursuant to Section 9.1(a) thereof. Except as otherwise set forth in the Merger Agreement, none of parties shall have any further liability thereunder.

     

    Upon termination of the Merger Agreement, the Stockholder Support Agreement (as defined in the Merger Agreement), the Sponsor Support Agreement (as defined in the Merger Agreement) and the Parent Support Agreement (as defined in the Merger Agreement) terminated pursuant to their terms.

     

    The foregoing summary of the letter agreement is qualified in its entirety by the text of the letter agreement, a copy of which is attached as Exhibit 10.1 hereto and is incorporated herein by reference. The foregoing descriptions of the Merger Agreement, the Stockholder Support Agreement, the Sponsor Support Agreement and the Parent Support Agreement are qualified in their entirety by reference to the full text of the Merger Agreement, the form of Stockholder Support Agreement, the form of Sponsor Support Agreement and the form of Parent Support Agreement, copies of which were filed as Exhibit 2.1, Exhibit 10.1, Exhibit 10.2 and Exhibit 10.3, respectively, to the Current Report on Form 8-K filed by FoxWayne on September 20, 2022, which are incorporated herein by reference.

     

    Forward Looking Statements

     

    Certain statements made herein are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are based on the opinions and estimates of management of FoxWayne, as of the date such statements are made, and they are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the occurrence of any event, change or other circumstances that could give rise to a delay in or the failure to close a future potential business combination, the amount of redemptions, the ability to retain key personnel and the ability to achieve stockholder and regulatory approvals, industry trends, legislation or regulatory requirements and developments in the global economy as well as the public health crisis related to the coronavirus (COVID-19) pandemic and resulting significant negative effects to the global economy and significant volatility and disruption of financial markets, increased operating costs and the impact of government shutdowns. Additional information on these and other factors that may cause actual results and FoxWayne’s performance to differ materially is included in FoxWayne’s periodic reports filed with the SEC. Copies of FoxWayne’s filings with the SEC are available publicly on the SEC’s website at www.sec.gov or may be obtained by contacting FoxWayne. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. These forward-looking statements are made only as of the date hereof, and FoxWayne undertakes no obligations to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Exhibit
    10.1   Letter Agreement, dated as of January 12, 2023, by and among FoxWayne, Merger Sub, Clover and the Stockholders’ Representative
         
    104   Cover Page Interactive Data File (embedded within the XBRL document)

     

    -2-

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      FoxWayne Enterprises Acquisition Corp.
         
    Date: January 19, 2023 By: /s/ Robb Knie
      Name:  Robb Knie
      Title: Chief Executive Officer

     

    -3-

    Get the next $FOXW alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FOXW

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FOXW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FOXWAYNE ENTERPRISES ACQUISITION CORP. ANNOUNCES CHANGE OF SPECIAL MEETING DATE AND INCREASE IN ITS CONTRIBUTION TO THE TRUST ACCOUNT FOR EXTENSION PROPOSAL

    NEW YORK, Nov. 29, 2022 /PRNewswire/ -- FoxWayne Enterprises Acquisition Corp. ("FoxWayne" or the "Company") (Nasdaq: "FOXW", "FOXWU", "FOXWW") announced today that its special meeting of stockholders (the "Special Meeting") originally scheduled for Wednesday, November 30, 2022, is being postponed to Tuesday December 13, 2022. At the Special Meeting, stockholders will be asked to vote on the following proposals: (1) a proposal to approve an amendment (the "Extension Amendment") to the Company's Second Amended and Restated Certificate of Incorporation to extend the date by which the Company must consummate a business combination for three months, from January 22, 2023 (the "Original Terminati

    11/29/22 5:20:00 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Live Streaming Social Entertainment Platform Powering the Creator Economy, Clover Inc., to Merge with Special Purpose Acquisition Company, FoxWayne Enterprises Acquisition Corp., to Become Public Company

    New entity poised to accelerate the development of Clover's next generation platform for live streaming with a suite of new product introductions. Clover has a growing user base of over 9 million with almost 90% of users between 18-39 years old.  Clover is targeting a launch of VR ('Virtual Reality') Dating and VR Live Streaming in Q4 2023. NEW YORK, Sept. 20, 2022 /PRNewswire/ -- Clover Inc. ("Clover" or the "Company"), a highly rated live streaming company focused on Gen Z and Millennial audiences and creators, and FoxWayne Enterprises Acquisition Corp. (NASDAQ: FOXW, FOXWW) ("FoxWayne"), a special purpose acquisition company ("SPAC"), today announced they have entered into a definitive bu

    9/20/22 8:08:00 AM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aerami Therapeutics Holdings, Inc. and FoxWayne Enterprises Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement

    DURHAM, N.C. and NEW YORK, March 4, 2022 /PRNewswire/ -- Aerami Therapeutics Holdings, Inc. ("Aerami"), a biopharmaceutical company focused on developing inhaled therapies to treat severe respiratory and chronic diseases, and FoxWayne Enterprises Acquisition Corp. (NASDAQ:FOXW) ("FoxWayne"), a publicly traded special purpose acquisition company ("SPAC"), announced today that they have mutually agreed to terminate their previously announced business combination agreement, effective immediately. In light of current unfavorable market conditions, Aerami and FoxWayne believe that

    3/4/22 4:30:00 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOXW
    SEC Filings

    View All

    SEC Form 15-12G filed by FoxWayne Enterprises Acquisition Corp.

    15-12G - FoxWayne Enterprises Acquisition Corp. (0001829999) (Filer)

    2/6/23 5:17:14 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by FoxWayne Enterprises Acquisition Corp.

    25-NSE - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    1/27/23 4:38:29 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by FoxWayne Enterprises Acquisition Corp.

    425 - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    1/24/23 5:27:10 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOXW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by FoxWayne Enterprises Acquisition Corp. (Amendment)

    SC 13G/A - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    2/13/24 7:35:39 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by FoxWayne Enterprises Acquisition Corp. (Amendment)

    SC 13G/A - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    2/12/24 11:00:29 AM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by FoxWayne Enterprises Acquisition Corp. (Amendment)

    SC 13G/A - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    3/10/23 4:03:05 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care